The tweet was deleted by the author.
But we saved everything 🙂.
Lexicon Pharmaceuticals is set to unveil data from its clinical programs at the American College of Cardiology event this week. The company will present analyses from the SCORED and SOTA P CARDIA studies through both oral and poster sessions.
These presentations are expected to offer new insights into Lexicon Pharmaceuticals' ongoing research pipeline. Further details on the clinical findings and potential implications for future therapies will be available during the conference.
Lexicon Pharmaceuticals has previously advanced non-opioid approaches in chronic pain treatment, as detailed in its development of alternative therapies. The company has also outlined research targeting ACSL5 for obesity and weight management in an earlier study announcement. These prior efforts demonstrate Lexicon's focus on diversified therapeutic pipelines.